Proteins and Peptides

11 Dec 2017 PharmaMar Presents Positive Results of the Pivotal Phase III Trial with Plitidepsin in Multiple Myeloma During the ASH Meeting
11 Dec 2017 Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology Conference
11 Dec 2017 Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
09 Dec 2017 ARMO BioSciences Presents Data from its Phase 1b Trial in Non-Small Cell Lung Cancer at ESMO Immuno Oncology Congress 2017
08 Dec 2017 ARMO BioSciences Presents Efficacy Data from its Phase 1b Trial in Patients with Metastatic Renal Cell Carcinoma at ESMO Immuno-Oncology Congress 2017
08 Dec 2017 ERYTECH Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML
08 Dec 2017 Asklepion Pharmaceuticals Presents Phase 1b/2a Clinical Trial Data for IV-Citrulline at the Pediatric Cardiac Intensive Care Society 13th Annual International Meeting
08 Dec 2017 Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy (NPDR) Discontinued due to Slow Recruitment Rate
08 Dec 2017 Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine
07 Dec 2017 Pieris Pharmaceuticals Announces Ethics and Regulatory Clearance to Begin Clinical Testing of Inhaled Respiratory Program, PRS-060/AZD1402
07 Dec 2017 Zealand Pharma initiates the pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes
06 Dec 2017 Ozempic® (semaglutide) approved in the US
05 Dec 2017 Revance’s RT002 Meets Primary and All Secondary Endpoints, Achieves 6-Month Duration in Pivotal SAKURA Phase 3 Trials for Glabellar Lines
04 Dec 2017 BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML
04 Dec 2017 La Jolla Pharmaceutical Company Announces Initiation of Pivotal Clinical Study of LJPC‑401 in Patients with Beta Thalassemia
04 Dec 2017 Sanofi's Toujeo® met main objective in head-to-head study versus insulin degludec
29 Nov 2017 Protalix BioTherapeutics Completes Enrollment in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis
29 Nov 2017 Aeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase 1/2 Trial with Pegzilarginase (AEB1102)
27 Nov 2017 Pharming Submits Supplemental Biologics License Application to FDA for RUCONEST® for Prophylaxis of Hereditary Angioedema Attacks
17 Nov 2017 Medicenna Presents Updates on Phase 2b Clinical Trial of MDNA55 at the Annual Meeting of the Society of Neuro-Oncology
16 Nov 2017 Sobi™ - First Patient Randomised in a Phase 3 Study Evaluating Safety and Efficacy of Anakinra in the Treatment of Still's Disease
15 Nov 2017 FDA approves treatment for rare genetic enzyme disorder
14 Nov 2017 Recruitment completed in trial to evaluate the optimal dosing frequency for Zealand's long-acting GLP-2 analog glepaglutide
12 Nov 2017 First Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017
10 Nov 2017 New Data on FORTEO® (teriparatide [rDNA origin] injection) Showed Reduced Risk for New Vertebral and Clinical Fractures in Postmenopausal Women with Severe Osteoporosis

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top